A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Clinical trial NCT03759366 · COMPLETED

Trial details

NCT number: NCT03759366
Sponsor: Alexion Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Myasthenia Gravis Myasthenia Gravis, Juvenile Form Myasthenia Gravis, Generalized

Start date: 2018-12-28
Primary completion: 2022-01-06
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.